23andMe customers requesting deletion of genetic data
Nearly 2 million 23andMe customers have requested deletion of their genetic data following bankruptcy and pending sale to Regeneron. Regeneron plans to use the data for drug discovery while upholding privacy practices. States have filed a lawsuit against the sale.
Key Points
- Regeneron plans to utilize 23andMe's genetic data for drug discovery efforts
- Customers can request deletion of their genetic data but some information will be retained for legal compliance
Pros
- Customers have the option to request deletion of their genetic data from 23andMe
Cons
- Concerns about potential misuse or unauthorized transfer of genetic data following bankruptcy and sale to Regeneron
- Privacy concerns raised by customers and privacy advocates
- Lawsuit filed by states challenging the sale of 23andMe's customer data